Free Trial
NASDAQ:AMRN

Amarin Q2 2023 Earnings Report

Amarin logo
$10.91 -0.07 (-0.64%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$10.90 -0.01 (-0.09%)
As of 05/2/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.80
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Amarin Revenue Results

Actual Revenue
$80.17 million
Expected Revenue
$73.40 million
Beat/Miss
Beat by +$6.77 million
YoY Revenue Growth
N/A

Amarin Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 2, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Amarin's Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Amarin Earnings Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Zacks Research Has Bullish Estimate for Amarin Q1 Earnings
See More Amarin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email.

About Amarin

Amarin (NASDAQ:AMRN), a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

View Amarin Profile

More Earnings Resources from MarketBeat